Acutaas Chemicals Ltd

Acutaas Chemicals Ltd

3,947.75
INR
+4.00
(+0.10%)
53.36EPS
61.13P/E
268.47BMarket Cap
Feb 14Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
32.73
32.88
46.14
76.02
84.13
97.23
124.8
162.33
193.26
Basic EPS, GAAP
3.2
3.77
7.41
10.52
11.43
5.83
19.81
43.51
53.64
Free Cash Flow per Basic Share
2.04
3.72
-10.86
-6.68
-4.24
-25.84
-9.52
-4.37
- -
Dividend per Share
- -
- -
- -
- -
1.5
1.49
1.53
1.5
- -
Book Value per Share
11.28
15.34
22.91
71.67
81.5
91.38
159.97
201.97
226.87
Tangible Book Value per Share
8.39
12.19
19.38
68
75.82
82.28
152.02
188.35
213.38
Basic Weighted Avg Shares
73
73
73
68
73
73
80
82
82
Sales/Revenue/Turnover
2,385
2,396
3,362
5,201
6,131
7,130
10,000
13,290
15,821
Operating Margin (%)
17.64
15.97
22.73
18.28
18.11
15.77
20.55
33.48
36.77
Depreciation Expense
26
35
42
101
123
161
266
360
420
Net Income, GAAP
233
275
540
719
833
428
1,587
3,563
4,392
Effective Tax Rate (%)
33.65
20.96
24.72
21.33
25.75
40.53
25.79
26.18
26.86
Profit Margin (%)
9.77
11.46
16.06
13.83
13.59
6
15.87
26.81
27.76
Working Capital
185
264
502
2,998
2,943
2,081
5,894
6,505
7,586
LT Debt
221
199
726
6
6
1,136
48
91
93
Total Equity
822
1,118
1,669
5,223
5,940
6,828
13,201
17,108
19,204
Return on Invested Capital (%)
- -
19.38
24.08
18.05
14.61
6.4
13.67
21.32
- -
Return on Capital (%)
- -
20.64
24.39
18.63
15.18
5.39
14.44
23.26
- -
Return on Common Equity (%)
- -
28.31
38.74
20.88
14.92
6.75
16
24.05
- -

Capital Structure

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
265
- -
59
LT Borrowings
- -
- -
- -
LT Finance Leases
91
- -
93
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
82
82
82
Market Capitalization
209,447
288,596
268,468

Working Capital

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
8,813
- -
10,120
Cash, Cash Equivalents & STI
2,248
- -
3,068
Accounts Receivable, Net
3,626
- -
3,583
Inventories
2,313
- -
2,803
Total Current Liabilities
2,308
- -
2,534
Payables & Accruals
- -
- -
- -
ST Debt
265
- -
59
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
72.9%
29.59%
Free Cash Flow
- -
65.26%
-53.07%
Net Income, GAAP
- -
79.18%
124.46%
Sales/Revenue/Turnover
- -
32.41%
32.9%
Total Cash Common Dividend
- -
- -
0.02%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,767
2,467
2,750
3,016
10,000
2026
2,072
- -
3,932
4,224
13,290
2027
3,297
4,369
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.83
4.69
5.68
7.63
19.81
2026
5.41
8.82
13.19
16.09
43.51
2027
9.07
15.29
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.53
2026
- -
- -
- -
- -
1.5
2027
- -
- -
- -
- -
- -

Company Description

CEO
Nareshkumar R. Patel
Full Time Employees
1,713
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Plot No. 440/4, 5 & 6 Surat GU India 394230
IPO Date
Sep 14, 2021
Business
Acutaas Chemicals Limited (ACUTAAS.NS) engages in the research, development, manufacture and sale of pharmaceutical intermediates and specialty chemicals in India and internationally. The company offers advanced pharmaceutical intermediates and active pharmaceutical ingredients for regulated and generic applications, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant and anticoagulant therapies such as Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban; specialty chemicals for agrochemicals, cosmetics and polymers; parabens and parabens formulations; salicylic acid; electrolyte additives including Vinylene Carbonate and Fluoro Vinylene Carbonate; and other fine chemicals used in cosmetics, dyes, polymers, agrochemicals, animal foods and personal care industries. It provides custom synthesis, contract development and manufacturing organization (CDMO) services through cGMP-compliant facilities equipped with R&D laboratories, serving pharmaceutical, personal care, agrochemical and polymer sectors across more than 27 countries in the Americas, Europe and Asia. Founded in 2004 and headquartered in Surat, India, with manufacturing units in Sachin, Ankleshwar and Jhagadia in Gujarat, the company operates as a globally integrated intermediates provider with approximately 1,465 employees. In recent developments, Acutaas Chemicals changed its name from Ami Organics Limited in May 2025; acquired a 55% stake in Baba Fine Chemicals in fiscal 2024 and two units from Gujarat Organics Limited in 2021; commissioned Block 2 at its Ankleshwar CDMO facility in Q3 fiscal 2025 and began supplying under a CDMO contract with Fermion from Block 3; made its Ankleshwar Unit II GMP-compliant following a virtual audit by Japan's PMDA; and plans to commission a new electrolyte additives plant at Jhagadia by H1 fiscal 2026 with 2,000 MTPA capacity each for Vinylene Carbonate and Fluoro Vinylene Carbonate, targeting EV battery manufacturers.